HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

“However, the immune system, if given appropriate signals, can be modulated towards providing an appropriate, efficacious, and lasting disease-modifying immunoglobulin G (IgG)-mediated response ...

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

This makes it a promising candidate for treating diseases that rely on IgG-mediated immune responses. The implications of this discovery extend far beyond MG. IgG-mediated pathologies—from ...

including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as ...

COVID-19 has little impact on patients with dermatological immune-mediated inflammatory diseases, with effective ...

NEW HAVEN, CT, USA I March 3, 2025 I Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

(RTTNews) - Johnson & Johnson (JNJ), on Thursday announced the publication of new data on nipocalimab, an investigational drug designed to treat IgG-driven alloantibody and autoantibody diseases.

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...